苦参素与贺普丁、迈普新联合序贯治疗慢性乙型肝炎59例临床观察

目的 了解苦参素与贺普丁、迈普新（胸腺肽a1）联合治疗慢性乙型肝炎的临床疗效.方法 将118例HBeAg阳性的慢性乙型肝炎患者随机分为治疗组和对照组.治疗组59例,同时使用苦参素、贺普丁、迈普新13周,随后使用贺普丁及迈普新13周,最后单用贺普丁26周;对照组59例单用同样剂量贺普丁52周.疗程中定期检测血常规、谷丙转氨酶（ALT）、HBeAg、抗-HBe、HBV DNA、透明质酸酶（HA）.结果 全部患者完成1年治疗.治疗组ALT、HA复常率,HBeAg/抗-HBe血清转换率、HBV DNA阴转率明显高于对照组（分别为81.6%和53.1%,P＜0.005;44.9%和22.4%,P＜0.025;42.9%和20.4%,P＜0.025;79.6%和51.0%,P＜0.005）.结论 苦参素与贺普丁、迈普新联合治疗慢性乙型肝炎疗效优于单用贺普丁.

Clinical Study on Marine Combined with Lamivudine and Thymosin a1 in the Treatment of Chronic Hepatitis B

Objective To evaluate the clinical efficacy of combination therapy of marine,lamivudine and thymosin a1 in chronic hepatitis B.Methods 118 chronic hepatitis B patients were enrolled and randomized into the therapy group and the control group.59 cases in the therapy group received marine,lamivudine and thymosin a1 for 13 weeks,then lamivudine and thymosin al for 13 weeks.At last lamivudine for 26 weeks;49 cases in the control group received lamivudine for 52 weeks.During the treatment blood routine examination of ALT,HBeAg,anti HBe,HBV DNA and HA were termly checked and measured.Results All 118 patients completed the study.The rates for ALT and HA to recover to normal and the rates for HBeAg/anti-HBe and HBV DNA to change to be negative in combination group were superior to those in Lamivudine group.(81.6% vs 51.3%;P<0.005;44.9% vs 22.4%;P<0.025;42.9% vs 20.4%;P<0.025;79.6% vs 51.0%,P<0.005).The efficacy of combination herapy appeared to be better than lamivudine group.Conclusion Marine combined with lamivudine and thymosin al in the treatment of chronic hepatitis B is better than single lamivudine.